Reference Code: GMDHC3574IDB Publication Date: May 2013 … · SAMPLE Pancreatic Cancer – Pipeline Review, H1 2013 Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub

SAMPLE

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)

Pancreatic Cancer – Pipeline Review, H1 2013

Reference Code: GMDHC3574IDB

Publication Date: May 2013

SAMPLEPancreatic Cancer – Pipeline Review, H1 2013

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)

Table of Contents

Table of Contents .................................................................................................................................................................................... 2 

List of Tables ...................................................................................................................................................................................... 8 

List of Figures .................................................................................................................................................................................. 13 

Introduction ........................................................................................................................................................................................... 14 

Global Markets Direct Report Coverage ......................................................................................................................................... 14 

Pancreatic Cancer Overview................................................................................................................................................................ 15 

Therapeutics Development .................................................................................................................................................................. 16 

An Overview of Pipeline Products for Pancreatic Cancer .............................................................................................................. 16 

Pancreatic Cancer Therapeutics under Development by Companies ................................................................................................ 18 

Pancreatic Cancer Therapeutics under Investigation by Universities/Institutes ................................................................................. 32 

Late Stage Products ............................................................................................................................................................................. 35 

Comparative Analysis ...................................................................................................................................................................... 35 

Mid Clinical Stage Products ................................................................................................................................................................. 36 

Comparative Analysis ...................................................................................................................................................................... 36 

Early Clinical Stage Products ............................................................................................................................................................... 37 

Comparative Analysis ...................................................................................................................................................................... 37 

Discovery and Pre-Clinical Stage Products ......................................................................................................................................... 38 

Comparative Analysis ...................................................................................................................................................................... 38 

Pancreatic Cancer Therapeutics – Products under Development by Companies .............................................................................. 39 

Pancreatic Cancer Therapeutics – Products under Investigation by Universities/Institutes ............................................................... 59 

Companies Involved in Pancreatic Cancer Therapeutics Development ............................................................................................. 62 

Bristol-Myers Squibb Company ...................................................................................................................................................... 62 

F. Hoffmann-La Roche Ltd. ............................................................................................................................................................. 63 

Amgen Inc. ...................................................................................................................................................................................... 64 

Sanofi-Aventis ................................................................................................................................................................................. 65 

AstraZeneca PLC ............................................................................................................................................................................ 66 

Eli Lilly and Company ...................................................................................................................................................................... 67 

Viralytics Ltd. ................................................................................................................................................................................... 68 

GlaxoSmithKline plc ........................................................................................................................................................................ 69 

Tekmira Pharmaceuticals Corp. ...................................................................................................................................................... 70 

Genentech, Inc. ............................................................................................................................................................................... 71 

Gilead Sciences, Inc. ....................................................................................................................................................................... 72 

Biotest AG ....................................................................................................................................................................................... 73 

Merck & Co., Inc. ............................................................................................................................................................................. 74 

AbGenomics International, Inc. ....................................................................................................................................................... 75 

Oxford BioMedica plc ...................................................................................................................................................................... 76 

Plexxikon Inc. .................................................................................................................................................................................. 77 

FibroGen, Inc. .................................................................................................................................................................................. 78 

MediGene AG .................................................................................................................................................................................. 79 

Nanotherapeutics, Inc. .................................................................................................................................................................... 80 

Prolexys Pharmaceuticals, Inc. ....................................................................................................................................................... 81 

ZIOPHARM Oncology, Inc. ............................................................................................................................................................. 82 

SAMPLEPancreatic Cancer – Pipeline Review, H1 2013

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3)

Novartis AG ..................................................................................................................................................................................... 83 

Samyang Corporation ..................................................................................................................................................................... 84 

Aphios Corporation .......................................................................................................................................................................... 85 

Astellas Pharma Inc. ....................................................................................................................................................................... 86 

CK Life Sciences Int'l., (Holdings) Inc. ............................................................................................................................................ 87 

Eisai Co., Ltd. .................................................................................................................................................................................. 88 

SuperGen, Inc. ................................................................................................................................................................................ 89 

Taiho Pharmaceutical Co., Ltd. ....................................................................................................................................................... 90 

Zeria Pharmaceutical Co Ltd ........................................................................................................................................................... 91 

Silence Therapeutics plc. ................................................................................................................................................................ 92 

Exelixis, Inc. ..................................................................................................................................................................................... 93 

Aduro BioTech ................................................................................................................................................................................. 94 

Celgene Corporation ....................................................................................................................................................................... 95 

Bayer AG ......................................................................................................................................................................................... 96 

Incyte Corporation ........................................................................................................................................................................... 97 

Halozyme Therapeutics .................................................................................................................................................................. 98 

Merck KGaA .................................................................................................................................................................................... 99 

Advaxis, Inc. .................................................................................................................................................................................. 100 

EntreMed, Inc. ............................................................................................................................................................................... 101 

Momenta Pharmaceuticals, Inc. .................................................................................................................................................... 102 

Anavex Life Sciences Corp. .......................................................................................................................................................... 103 

ValiRx Plc ...................................................................................................................................................................................... 104 

ImmunoCellular Therapeutics, Ltd. ............................................................................................................................................... 105 

IMMUNOMEDICS, INC ................................................................................................................................................................. 106 

Lorus Therapeutics Inc .................................................................................................................................................................. 107 

Marshall Edwards, Inc. .................................................................................................................................................................. 108 

MethylGene Inc ............................................................................................................................................................................. 109 

Bionomics Limited ......................................................................................................................................................................... 110 

Molecular Insight Pharmaceuticals, Inc. ....................................................................................................................................... 111 

Northwest Biotherapeutics, Inc. .................................................................................................................................................... 112 

Oncolytics Biotech Inc. .................................................................................................................................................................. 113 

Patrys Limited ................................................................................................................................................................................ 114 

Peregrine Pharmaceuticals, Inc. ................................................................................................................................................... 115 

Critical Outcome Technologies Inc. .............................................................................................................................................. 116 

La Jolla Pharmaceutical Company ............................................................................................................................................... 117 

Telik, Inc. ....................................................................................................................................................................................... 118 

VioQuest Pharmaceuticals, Inc. .................................................................................................................................................... 119 

CytRx Corporation ......................................................................................................................................................................... 120 

Champions Biotechnology, Inc. .................................................................................................................................................... 121 

Oncogenex Pharmaceuticals, Inc. ................................................................................................................................................ 122 

Pharmacyclics, Inc. ....................................................................................................................................................................... 123 

ProMetic Life Sciences Inc. ........................................................................................................................................................... 124 

Green Cross Corporation .............................................................................................................................................................. 125 

OncoTherapy Science, Inc. ........................................................................................................................................................... 126 

SAMPLEPancreatic Cancer – Pipeline Review, H1 2013

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(4)

Quest PharmaTech Inc. ................................................................................................................................................................ 127 

Threshold Pharmaceuticals, Inc. ................................................................................................................................................... 128 

Synta Pharmaceuticals Corp. ........................................................................................................................................................ 129 

CrystalGenomics, Inc. ................................................................................................................................................................... 130 

Natco Pharma Limited ................................................................................................................................................................... 131 

Sareum Holdings plc ..................................................................................................................................................................... 132 

DiaMedica Inc. ............................................................................................................................................................................... 133 

NanoCarrier Co., Ltd. .................................................................................................................................................................... 134 

Rexahn Pharmaceuticals, Inc. ...................................................................................................................................................... 135 

MabVax Therapeutics, Inc. ........................................................................................................................................................... 136 

Nanobiotix ...................................................................................................................................................................................... 137 

Morphotek, Inc. .............................................................................................................................................................................. 138 

Cancer Research Technology Limited .......................................................................................................................................... 139 

Antisense Pharma GmbH ............................................................................................................................................................. 140 

Colby Pharmaceutical Company ................................................................................................................................................... 141 

Wilex AG ........................................................................................................................................................................................ 142 

INSYS Therapeutics, Inc. .............................................................................................................................................................. 143 

Aurigene Discovery Technologies Limited .................................................................................................................................... 144 

Philogen S.p.A. .............................................................................................................................................................................. 145 

Multimmune GmbH ....................................................................................................................................................................... 146 

Nerviano Medical Sciences S.r.l. .................................................................................................................................................. 147 

Wellstat Therapeutics Corporation ................................................................................................................................................ 148 

Hutchison MediPharma Limited .................................................................................................................................................... 149 

ERYtech Pharma ........................................................................................................................................................................... 150 

Advantagene, Inc. ......................................................................................................................................................................... 151 

Alethia Biotherapeutics Inc. ........................................................................................................................................................... 152 

NormOxys, Inc. .............................................................................................................................................................................. 153 

Ascenta Therapeutics, Inc. ............................................................................................................................................................ 154 

Gene Signal International SA. ....................................................................................................................................................... 155 

Heat Biologics, Inc. ........................................................................................................................................................................ 156 

MacroGenics, Inc. ......................................................................................................................................................................... 157 

Antyra, Inc. .................................................................................................................................................................................... 158 

OncoMed Pharmaceuticals, Inc. ................................................................................................................................................... 159 

TetraLogic Pharmaceuticals .......................................................................................................................................................... 160 

Azaya Therapeutics, Inc. ............................................................................................................................................................... 161 

Merrimack Pharmaceuticals, Inc. .................................................................................................................................................. 162 

Nobelpharma Co., Ltd. .................................................................................................................................................................. 163 

INNOPHARMAX, INC. .................................................................................................................................................................. 164 

RESprotect GmbH ......................................................................................................................................................................... 165 

Jennerex Biotherapeutics, Inc. ...................................................................................................................................................... 166 

Stemline Therapeutics, Inc. ........................................................................................................................................................... 167 

Axcentua Pharmaceuticals AB ...................................................................................................................................................... 168 

BioCancell Therapeutics, Inc. ....................................................................................................................................................... 169 

Cornerstone Pharmaceuticals, Inc. ............................................................................................................................................... 170 

SAMPLEPancreatic Cancer – Pipeline Review, H1 2013

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(5)

Onconova Therapeutics, Inc ......................................................................................................................................................... 171 

Pharminox Limited ......................................................................................................................................................................... 172 

Viral Genetics, Inc. ........................................................................................................................................................................ 173 

KangLaiTe USA ............................................................................................................................................................................. 174 

NovaLead Pharma Pvt. Ltd. .......................................................................................................................................................... 175 

Esperance Pharmaceuticals, Inc. ................................................................................................................................................. 176 

Omeros Corporation ...................................................................................................................................................................... 177 

Transtech Pharma, Inc. ................................................................................................................................................................. 178 

Welichem Biotech Inc. ................................................................................................................................................................... 179 

Oncolys BioPharma Inc. ................................................................................................................................................................ 180 

Globeimmune, Inc. ........................................................................................................................................................................ 181 

NewLink Genetics Corporation ..................................................................................................................................................... 182 

Tragara Pharmaceuticals, Inc. ...................................................................................................................................................... 183 

PharmaMar, S.A. ........................................................................................................................................................................... 184 

CG Therapeutics, Inc. ................................................................................................................................................................... 185 

Quintessence Biosciences, Inc. .................................................................................................................................................... 186 

AmpliMed Corporation................................................................................................................................................................... 187 

AB Science .................................................................................................................................................................................... 188 

Tigris Pharmaceuticals, Inc. .......................................................................................................................................................... 189 

Genelux Corporation ..................................................................................................................................................................... 190 

Lipopharma .................................................................................................................................................................................... 191 

Nereus Pharmaceuticals, Inc. ....................................................................................................................................................... 192 

Medisyn Technologies, Inc. ........................................................................................................................................................... 193 

Oncovir, Inc. .................................................................................................................................................................................. 194 

Keystone Nano, Inc. ...................................................................................................................................................................... 195 

Perseus Proteomics, Inc. .............................................................................................................................................................. 196 

Pique Therapeutics ....................................................................................................................................................................... 197 

3-V Biosciences, Inc. ..................................................................................................................................................................... 198 

Cancer Therapeutics CRC Pty Ltd ................................................................................................................................................ 199 

Eleison Pharmaceuticals, Inc. ....................................................................................................................................................... 200 

Targa Therapeutics Corp. ............................................................................................................................................................. 201 

NuCana BioMed Limited ............................................................................................................................................................... 202 

KAEL-GemVax .............................................................................................................................................................................. 203 

Nuvilex, Inc. ................................................................................................................................................................................... 204 

iCeutica, Inc. .................................................................................................................................................................................. 205 

Mebiopharm Co., Ltd. .................................................................................................................................................................... 206 

Polaris Group ................................................................................................................................................................................. 207 

DEKK-TEC, Inc. ............................................................................................................................................................................ 208 

IkerChem S.L................................................................................................................................................................................. 209 

Regulon Inc. .................................................................................................................................................................................. 210 

TAU Therapeutics, LLC ................................................................................................................................................................. 211 

Gradalis Inc. .................................................................................................................................................................................. 212 

CytoVac A/S .................................................................................................................................................................................. 213 

Oncozyme Pharma Inc. ................................................................................................................................................................. 214 

SAMPLEPancreatic Cancer – Pipeline Review, H1 2013

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(6)

CytomX, LLC. ................................................................................................................................................................................ 215 

Pancreatic Cancer – Therapeutics Assessment ................................................................................................................................ 216 

Assessment by Monotherapy Products ........................................................................................................................................ 216 

Assessment by Combination Products ......................................................................................................................................... 217 

Assessment by Route of Administration ....................................................................................................................................... 218 

Assessment by Molecule Type ..................................................................................................................................................... 221 

Drug Profiles ....................................................................................................................................................................................... 224 

ganitumab - Drug Profile ............................................................................................................................................................... 224 

Product Description .................................................................................................................................................................. 224 

Mechanism of Action ................................................................................................................................................................ 224 

R&D Progress ........................................................................................................................................................................... 224 

paclitaxel albumin-bound - Drug Profile ........................................................................................................................................ 227 

Product Description .................................................................................................................................................................. 227 

Mechanism of Action ................................................................................................................................................................ 227 

R&D Progress ........................................................................................................................................................................... 227 

glufosfamide - Drug Profile ............................................................................................................................................................ 229 

Product Description .................................................................................................................................................................. 229 

Mechanism of Action ................................................................................................................................................................ 229 

R&D Progress ........................................................................................................................................................................... 229 

edotreotide labeled yttrium 90 - Drug Profile ................................................................................................................................ 231 

Product Description .................................................................................................................................................................. 231 

Mechanism of Action ................................................................................................................................................................ 231 

R&D Progress ........................................................................................................................................................................... 231 

tertomotide - Drug Profile .............................................................................................................................................................. 233 

Product Description .................................................................................................................................................................. 233 

Mechanism of Action ................................................................................................................................................................ 233 

R&D Progress ........................................................................................................................................................................... 233 

TH-302 - Drug Profile .................................................................................................................................................................... 235 

Product Description .................................................................................................................................................................. 235 

Mechanism of Action ................................................................................................................................................................ 235 

R&D Progress ........................................................................................................................................................................... 235 

irinotecan hydrochloride nanoliposomal - Drug Profile ................................................................................................................. 242 

Product Description .................................................................................................................................................................. 242 

Mechanism of Action ................................................................................................................................................................ 242 

R&D Progress ........................................................................................................................................................................... 242 

rigosertib sodium - Drug Profile .................................................................................................................................................... 244 

Product Description .................................................................................................................................................................. 244 

Mechanism of Action ................................................................................................................................................................ 244 

R&D Progress ........................................................................................................................................................................... 244 

algenpantucel-L - Drug Profile ...................................................................................................................................................... 247 

Product Description .................................................................................................................................................................. 247 

Mechanism of Action ................................................................................................................................................................ 247 

R&D Progress ........................................................................................................................................................................... 247 

elpamotide - Drug Profile .............................................................................................................................................................. 249 

SAMPLEPancreatic Cancer – Pipeline Review, H1 2013

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(7)

Product Description .................................................................................................................................................................. 249 

Mechanism of Action ................................................................................................................................................................ 249 

R&D Progress ........................................................................................................................................................................... 249 

masitinib - Drug Profile .................................................................................................................................................................. 251 

Product Description .................................................................................................................................................................. 251 

Mechanism of Action ................................................................................................................................................................ 251 

R&D Progress ........................................................................................................................................................................... 251 

TH-302 + [gemcitabine hydrochloride] - Drug Profile ................................................................................................................... 253 

Product Description .................................................................................................................................................................. 253 

Mechanism of Action ................................................................................................................................................................ 253 

R&D Progress ........................................................................................................................................................................... 253 

nimotuzumab - Drug Profile .......................................................................................................................................................... 255 

Product Description .................................................................................................................................................................. 255 

Mechanism of Action ................................................................................................................................................................ 255 

R&D Progress ........................................................................................................................................................................... 255 

liposomal cisplatin - Drug Profile ................................................................................................................................................... 258 

Product Description .................................................................................................................................................................. 258 

Mechanism of Action ................................................................................................................................................................ 258 

R&D Progress ........................................................................................................................................................................... 258 

uridine triacetate - Drug Profile ..................................................................................................................................................... 260 

Product Description .................................................................................................................................................................. 260 

Mechanism of Action ................................................................................................................................................................ 260 

R&D Progress ........................................................................................................................................................................... 260 

(tegafur + gimeracil + oteracil potassium) - Drug Profile .............................................................................................................. 262 

Product Description .................................................................................................................................................................. 262 

Mechanism of Action ................................................................................................................................................................ 262 

R&D Progress ........................................................................................................................................................................... 262 

brivudine - Drug Profile ................................................................................................................................................................. 265 

Product Description .................................................................................................................................................................. 265 

Mechanism of Action ................................................................................................................................................................ 265 

R&D Progress ........................................................................................................................................................................... 265 

OCV-C01 - Drug Profile ................................................................................................................................................................ 267 

Product Description .................................................................................................................................................................. 267 

Mechanism of Action ................................................................................................................................................................ 267 

R&D Progress ........................................................................................................................................................................... 267 

Polyclonal Antibody Stimulator - Drug Profile ............................................................................................................................... 268 

Product Description .................................................................................................................................................................. 268 

Mechanism of Action ................................................................................................................................................................ 268 

R&D Progress ........................................................................................................................................................................... 268 

Pancreatic Cancer Therapeutics – Drug Profile Updates .................................................................................................................. 269 

Pancreatic Cancer Therapeutics – Discontinued Products ............................................................................................................... 293 

Pancreatic Cancer Therapeutics - Dormant Products ....................................................................................................................... 297 

Pancreatic Cancer – Product Development Milestones .................................................................................................................... 309 

Featured News & Press Releases ................................................................................................................................................ 309 

SAMPLEPancreatic Cancer – Pipeline Review, H1 2013

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(8)

Nov 14, 2012: NewLink Genetics Receives European Orphan Designation For Algenpantucel-L Immunotherapy To Treat Pancreatic Cancer .................................................................................................................................................................... 309 

Nov 13, 2012: Tiltan Pharma Announces Enrollment Of First US Patient In Phase II Clinical Trial Of TL-118 For Treatment Of Metastatic Pancreatic Cancer .................................................................................................................................................. 309 

Nov 12, 2012: Clovis Oncology Announces Outcome Of CO-101 In Pivotal LEAP Pancreatic Cancer Study ...................... 310 

Nov 09, 2012: OncoMed Pharma Presents Clinical Data On Anti-Notch2/3 Program At EORTC-NCI-AACR Meeting ........ 311 

Nov 09, 2012: Oncolytics Biotech Collaborators Present Positive Reolysin Trial Results And Research At EORTC-NCI-AACR Symposium ............................................................................................................................................................................... 312 

Oct 31, 2012: Nuvilex Signs Contract With ViruSure To Initiate Amplification Of Cells For Treatment Of Pancreatic Cancer .................................................................................................................................................................................................. 313 

Oct 30, 2012: AB Science Reports Phase III Study Results Of Masitinib In Combination With Gemzar For Treatment Of Pancreatic Cancer .................................................................................................................................................................... 313 

Oct 25, 2012: Novelos Announces Enrollment Of First Patient In Solid Tumor Imaging Trial With I-124-CLR1404 At University Of Wisconsin Carbone Cancer Center .................................................................................................................... 315 

Oct 24, 2012: Oncolytics Completes Patient Enrollment In US Phase II Study Investigating Reolysin In Combination With Gemcitabine In Patients With Pancreatic Cancer .................................................................................................................... 316 

Oct 22, 2012: Vaximm Completes Enrollment In Phase I/II Study Of Oral Cancer Therapeutic Vaccine VXM01 ................. 317 

Appendix ............................................................................................................................................................................................. 318 

Methodology .................................................................................................................................................................................. 318 

Coverage ....................................................................................................................................................................................... 318 

Secondary Research ..................................................................................................................................................................... 318 

Primary Research .......................................................................................................................................................................... 318 

Expert Panel Validation ................................................................................................................................................................. 318 

Disclaimer ...................................................................................................................................................................................... 319 

List of Tables

Number of Products Under Development for Pancreatic Cancer, H1 2013 ........................................................................................ 16 

Products under Development for Pancreatic Cancer – Comparative Analysis, H1 2013 ................................................................... 17 

Number of Products under Development by Companies, H1 2013 .................................................................................................... 19 

Number of Products under Development by Companies, H1 2013 (Contd..1) ................................................................................... 20 

Number of Products under Development by Companies, H1 2013 (Contd..2) ................................................................................... 21 

Number of Products under Development by Companies, H1 2013 (Contd..3) ................................................................................... 22 

Number of Products under Development by Companies, H1 2013 (Contd..4) ................................................................................... 23 

Number of Products under Development by Companies, H1 2013 (Contd..5) ................................................................................... 24 

Number of Products under Development by Companies, H1 2013 (Contd..6) ................................................................................... 25 

Number of Products under Development by Companies, H1 2013 (Contd..7) ................................................................................... 26 

Number of Products under Development by Companies, H1 2013 (Contd..8) ................................................................................... 27 

Number of Products under Development by Companies, H1 2013 (Contd..9) ................................................................................... 28 

Number of Products under Development by Companies, H1 2013 (Contd..10) ................................................................................. 29 

Number of Products under Development by Companies, H1 2013 (Contd..11) ................................................................................. 30 

Number of Products under Development by Companies, H1 2013 (Contd..12) ................................................................................. 31 

Number of Products under Investigation by Universities/Institutes, H1 2013 ..................................................................................... 33 

Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) .................................................................... 34 

Comparative Analysis by Late Stage Development, H1 2013 ............................................................................................................ 35 

Comparative Analysis by Mid Clinical Stage Development, H1 2013 ................................................................................................. 36 

SAMPLEPancreatic Cancer – Pipeline Review, H1 2013

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(9)

Comparative Analysis by Early Clinical Stage Development, H1 2013 .............................................................................................. 37 

Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 ......................................................................... 38 

Products under Development by Companies, H1 2013 ...................................................................................................................... 39 

Products under Development by Companies, H1 2013 (Contd..1) ..................................................................................................... 40 

Products under Development by Companies, H1 2013 (Contd..2) ..................................................................................................... 41 

Products under Development by Companies, H1 2013 (Contd..3) ..................................................................................................... 42 

Products under Development by Companies, H1 2013 (Contd..4) ..................................................................................................... 43 

Products under Development by Companies, H1 2013 (Contd..5) ..................................................................................................... 44 

Products under Development by Companies, H1 2013 (Contd..6) ..................................................................................................... 45 

Products under Development by Companies, H1 2013 (Contd..7) ..................................................................................................... 46 

Products under Development by Companies, H1 2013 (Contd..8) ..................................................................................................... 47 

Products under Development by Companies, H1 2013 (Contd..9) ..................................................................................................... 48 

Products under Development by Companies, H1 2013 (Contd..10) ................................................................................................... 49 

Products under Development by Companies, H1 2013 (Contd..11) ................................................................................................... 50 

Products under Development by Companies, H1 2013 (Contd..12) ................................................................................................... 51 

Products under Development by Companies, H1 2013 (Contd..13) ................................................................................................... 52 

Products under Development by Companies, H1 2013 (Contd..14) ................................................................................................... 53 

Products under Development by Companies, H1 2013 (Contd..15) ................................................................................................... 54 

Products under Development by Companies, H1 2013 (Contd..16) ................................................................................................... 55 

Products under Development by Companies, H1 2013 (Contd..17) ................................................................................................... 56 

Products under Development by Companies, H1 2013 (Contd..18) ................................................................................................... 57 

Products under Development by Companies, H1 2013 (Contd..19) ................................................................................................... 58 

Products under Investigation by Universities/Institutes, H1 2013 ....................................................................................................... 59 

Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) ...................................................................................... 60 

Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) ...................................................................................... 61 

Bristol-Myers Squibb Company, H1 2013 ............................................................................................................................................ 62 

F. Hoffmann-La Roche Ltd., H1 2013 .................................................................................................................................................. 63 

Amgen Inc., H1 2013............................................................................................................................................................................ 64 

Sanofi-Aventis, H1 2013 ...................................................................................................................................................................... 65 

AstraZeneca PLC, H1 2013 ................................................................................................................................................................. 66 

Eli Lilly and Company, H1 2013 ........................................................................................................................................................... 67 

Viralytics Ltd., H1 2013 ........................................................................................................................................................................ 68 

GlaxoSmithKline plc, H1 2013 ............................................................................................................................................................. 69 

Tekmira Pharmaceuticals Corp., H1 2013 ........................................................................................................................................... 70 

Genentech, Inc., H1 2013 .................................................................................................................................................................... 71 

Gilead Sciences, Inc., H1 2013 ............................................................................................................................................................ 72 

Biotest AG, H1 2013 ............................................................................................................................................................................. 73 

AbGenomics International, Inc., H1 2013 ............................................................................................................................................ 75 

Plexxikon Inc., H1 2013 ....................................................................................................................................................................... 77 

FibroGen, Inc., H1 2013 ....................................................................................................................................................................... 78 

MediGene AG, H1 2013 ....................................................................................................................................................................... 79 

Nanotherapeutics, Inc., H1 2013 ......................................................................................................................................................... 80 

Prolexys Pharmaceuticals, Inc., H1 2013 ............................................................................................................................................ 81 

ZIOPHARM Oncology, Inc., H1 2013 .................................................................................................................................................. 82 

SAMPLEPancreatic Cancer – Pipeline Review, H1 2013

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(10)

Novartis AG, H1 2013 .......................................................................................................................................................................... 83 

Samyang Corporation, H1 2013 .......................................................................................................................................................... 84 

Aphios Corporation, H1 2013 ............................................................................................................................................................... 85 

Astellas Pharma Inc., H1 2013 ............................................................................................................................................................ 86 

CK Life Sciences Int'l., (Holdings) Inc., H1 2013 ................................................................................................................................. 87 

Eisai Co., Ltd., H1 2013 ....................................................................................................................................................................... 88 

SuperGen, Inc., H1 2013 ..................................................................................................................................................................... 89 

Taiho Pharmaceutical Co., Ltd., H1 2013 ............................................................................................................................................ 90 

Zeria Pharmaceutical Co Ltd, H1 2013 ................................................................................................................................................ 91 

Exelixis, Inc., H1 2013 .......................................................................................................................................................................... 93 

Aduro BioTech, H1 2013 ...................................................................................................................................................................... 94 

Celgene Corporation, H1 2013 ............................................................................................................................................................ 95 

Bayer AG, H1 2013 .............................................................................................................................................................................. 96 

Incyte Corporation, H1 2013 ................................................................................................................................................................ 97 

Halozyme Therapeutics, H1 2013 ........................................................................................................................................................ 98 

Merck KGaA, H1 2013 ......................................................................................................................................................................... 99 

Advaxis, Inc., H1 2013 ....................................................................................................................................................................... 100 

EntreMed, Inc., H1 2013 .................................................................................................................................................................... 101 

Anavex Life Sciences Corp., H1 2013 ............................................................................................................................................... 103 

ValiRx Plc, H1 2013 ........................................................................................................................................................................... 104 

ImmunoCellular Therapeutics, Ltd., H1 2013 .................................................................................................................................... 105 

IMMUNOMEDICS, INC, H1 2013 ...................................................................................................................................................... 106 

Lorus Therapeutics Inc, H1 2013 ....................................................................................................................................................... 107 

Marshall Edwards, Inc., H1 2013 ....................................................................................................................................................... 108 

MethylGene Inc, H1 2013 .................................................................................................................................................................. 109 

Bionomics Limited, H1 2013 .............................................................................................................................................................. 110 

Molecular Insight Pharmaceuticals, Inc., H1 2013 ............................................................................................................................ 111 

Northwest Biotherapeutics, Inc., H1 2013 ......................................................................................................................................... 112 

Oncolytics Biotech Inc., H1 2013 ....................................................................................................................................................... 113 

Patrys Limited, H1 2013 ..................................................................................................................................................................... 114 

Peregrine Pharmaceuticals, Inc., H1 2013 ........................................................................................................................................ 115 

Critical Outcome Technologies Inc., H1 2013 ................................................................................................................................... 116 

La Jolla Pharmaceutical Company, H1 2013..................................................................................................................................... 117 

Telik, Inc., H1 2013 ............................................................................................................................................................................ 118 

VioQuest Pharmaceuticals, Inc., H1 2013 ......................................................................................................................................... 119 

CytRx Corporation, H1 2013 .............................................................................................................................................................. 120 

Champions Biotechnology, Inc., H1 2013 .......................................................................................................................................... 121 

Oncogenex Pharmaceuticals, Inc., H1 2013 ..................................................................................................................................... 122 

Pharmacyclics, Inc., H1 2013 ............................................................................................................................................................ 123 

ProMetic Life Sciences Inc., H1 2013 ................................................................................................................................................ 124 

Green Cross Corporation, H1 2013 ................................................................................................................................................... 125 

OncoTherapy Science, Inc., H1 2013 ................................................................................................................................................ 126 

Quest PharmaTech Inc., H1 2013 ..................................................................................................................................................... 127 

Threshold Pharmaceuticals, Inc., H1 2013 ........................................................................................................................................ 128 

SAMPLEPancreatic Cancer – Pipeline Review, H1 2013

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(11)

Synta Pharmaceuticals Corp., H1 2013 ............................................................................................................................................. 129 

CrystalGenomics, Inc., H1 2013 ........................................................................................................................................................ 130 

Natco Pharma Limited, H1 2013 ........................................................................................................................................................ 131 

Sareum Holdings plc, H1 2013 .......................................................................................................................................................... 132 

DiaMedica Inc., H1 2013 .................................................................................................................................................................... 133 

NanoCarrier Co., Ltd., H1 2013 ......................................................................................................................................................... 134 

Rexahn Pharmaceuticals, Inc., H1 2013 ........................................................................................................................................... 135 

MabVax Therapeutics, Inc., H1 2013 ................................................................................................................................................ 136 

Nanobiotix, H1 2013 ........................................................................................................................................................................... 137 

Morphotek, Inc., H1 2013 ................................................................................................................................................................... 138 

Cancer Research Technology Limited, H1 2013 ............................................................................................................................... 139 

Antisense Pharma GmbH, H1 2013 ................................................................................................................................................... 140 

Colby Pharmaceutical Company, H1 2013 ........................................................................................................................................ 141 

Wilex AG, H1 2013 ............................................................................................................................................................................. 142 

INSYS Therapeutics, Inc., H1 2013 ................................................................................................................................................... 143 

Aurigene Discovery Technologies Limited, H1 2013 ......................................................................................................................... 144 

Philogen S.p.A., H1 2013 ................................................................................................................................................................... 145 

Multimmune GmbH, H1 2013............................................................................................................................................................. 146 

Nerviano Medical Sciences S.r.l., H1 2013 ....................................................................................................................................... 147 

Wellstat Therapeutics Corporation, H1 2013 ..................................................................................................................................... 148 

Hutchison MediPharma Limited, H1 2013 ......................................................................................................................................... 149 

ERYtech Pharma, H1 2013 ................................................................................................................................................................ 150 

Alethia Biotherapeutics Inc., H1 2013 ................................................................................................................................................ 152 

NormOxys, Inc., H1 2013 ................................................................................................................................................................... 153 

Ascenta Therapeutics, Inc., H1 2013 ................................................................................................................................................. 154 

Gene Signal International SA., H1 2013 ............................................................................................................................................ 155 

Heat Biologics, Inc., H1 2013 ............................................................................................................................................................. 156 

MacroGenics, Inc., H1 2013............................................................................................................................................................... 157 

Antyra, Inc., H1 2013.......................................................................................................................................................................... 158 

OncoMed Pharmaceuticals, Inc., H1 2013 ........................................................................................................................................ 159 

TetraLogic Pharmaceuticals, H1 2013 ............................................................................................................................................... 160 

Azaya Therapeutics, Inc., H1 2013 .................................................................................................................................................... 161 

Merrimack Pharmaceuticals, Inc., H1 2013 ....................................................................................................................................... 162 

INNOPHARMAX, INC., H1 2013 ....................................................................................................................................................... 164 

RESprotect GmbH, H1 2013 .............................................................................................................................................................. 165 

Jennerex Biotherapeutics, Inc., H1 2013 ........................................................................................................................................... 166 

Stemline Therapeutics, Inc., H1 2013 ................................................................................................................................................ 167 

BioCancell Therapeutics, Inc., H1 2013 ............................................................................................................................................ 169 

Cornerstone Pharmaceuticals, Inc., H1 2013 .................................................................................................................................... 170 

Onconova Therapeutics, Inc, H1 2013 .............................................................................................................................................. 171 

Pharminox Limited, H1 2013 .............................................................................................................................................................. 172 

Viral Genetics, Inc., H1 2013 ............................................................................................................................................................. 173 

KangLaiTe USA, H1 2013 .................................................................................................................................................................. 174 

NovaLead Pharma Pvt. Ltd., H1 2013 ............................................................................................................................................... 175 

SAMPLEPancreatic Cancer – Pipeline Review, H1 2013

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(12)

Esperance Pharmaceuticals, Inc., H1 2013 ....................................................................................................................................... 176 

Omeros Corporation, H1 2013 ........................................................................................................................................................... 177 

Transtech Pharma, Inc., H1 2013 ...................................................................................................................................................... 178 

Welichem Biotech Inc., H1 2013 ........................................................................................................................................................ 179 

Oncolys BioPharma Inc., H1 2013 ..................................................................................................................................................... 180 

Globeimmune, Inc., H1 2013 ............................................................................................................................................................. 181 

NewLink Genetics Corporation, H1 2013 .......................................................................................................................................... 182 

Tragara Pharmaceuticals, Inc., H1 2013 ........................................................................................................................................... 183 

PharmaMar, S.A., H1 2013 ................................................................................................................................................................ 184 

CG Therapeutics, Inc., H1 2013 ........................................................................................................................................................ 185 

Quintessence Biosciences, Inc., H1 2013 ......................................................................................................................................... 186 

AB Science, H1 2013 ......................................................................................................................................................................... 188 

Tigris Pharmaceuticals, Inc., H1 2013 ............................................................................................................................................... 189 

Genelux Corporation, H1 2013 .......................................................................................................................................................... 190 

Lipopharma, H1 2013 ......................................................................................................................................................................... 191 

Nereus Pharmaceuticals, Inc., H1 2013 ............................................................................................................................................ 192 

Medisyn Technologies, Inc., H1 2013 ................................................................................................................................................ 193 

Oncovir, Inc., H1 2013 ....................................................................................................................................................................... 194 

Keystone Nano, Inc., H1 2013 ........................................................................................................................................................... 195 

Perseus Proteomics, Inc., H1 2013 ................................................................................................................................................... 196 

Pique Therapeutics, H1 2013 ............................................................................................................................................................ 197 

3-V Biosciences, Inc., H1 2013 .......................................................................................................................................................... 198 

Cancer Therapeutics CRC Pty Ltd, H1 2013 ..................................................................................................................................... 199 

Eleison Pharmaceuticals, Inc., H1 2013 ............................................................................................................................................ 200 

Targa Therapeutics Corp., H1 2013 .................................................................................................................................................. 201 

KAEL-GemVax, H1 2013 ................................................................................................................................................................... 203 

Nuvilex, Inc., H1 2013 ........................................................................................................................................................................ 204 

iCeutica, Inc., H1 2013 ....................................................................................................................................................................... 205 

Mebiopharm Co., Ltd., H1 2013 ......................................................................................................................................................... 206 

Polaris Group, H1 2013 ...................................................................................................................................................................... 207 

DEKK-TEC, Inc., H1 2013 .................................................................................................................................................................. 208 

IkerChem S.L., H1 2013 ..................................................................................................................................................................... 209 

Regulon Inc., H1 2013 ....................................................................................................................................................................... 210 

TAU Therapeutics, LLC, H1 2013 ...................................................................................................................................................... 211 

Gradalis Inc., H1 2013 ....................................................................................................................................................................... 212 

CytoVac A/S, H1 2013 ....................................................................................................................................................................... 213 

CytomX, LLC., H1 2013 ..................................................................................................................................................................... 215 

Assessment by Monotherapy Products, H1 2013 ............................................................................................................................. 216 

Assessment by Combination Products, H1 2013 .............................................................................................................................. 217 

Assessment by Stage and Route of Administration, H1 2013 .......................................................................................................... 220 

Assessment by Stage and Molecule Type, H1 2013 ......................................................................................................................... 223 

Pancreatic Cancer Therapeutics – Drug Profile Updates .................................................................................................................. 269 

Pancreatic Cancer Therapeutics – Discontinued Products ............................................................................................................... 293 

Pancreatic Cancer Therapeutics – Discontinued Products (Contd..1) .............................................................................................. 294 

SAMPLEPancreatic Cancer – Pipeline Review, H1 2013

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(13)

Pancreatic Cancer Therapeutics – Discontinued Products (Contd..2) .............................................................................................. 295 

Pancreatic Cancer Therapeutics – Discontinued Products (Contd..3) .............................................................................................. 296 

Pancreatic Cancer Therapeutics – Dormant Products ...................................................................................................................... 297 

Pancreatic Cancer Therapeutics – Dormant Products (Contd..1) ..................................................................................................... 298 

Pancreatic Cancer Therapeutics – Dormant Products (Contd..2) ..................................................................................................... 299 

Pancreatic Cancer Therapeutics – Dormant Products (Contd..3) ..................................................................................................... 300 

Pancreatic Cancer Therapeutics – Dormant Products (Contd..4) ..................................................................................................... 301 

Pancreatic Cancer Therapeutics – Dormant Products (Contd..5) ..................................................................................................... 302 

Pancreatic Cancer Therapeutics – Dormant Products (Contd..6) ..................................................................................................... 303 

Pancreatic Cancer Therapeutics – Dormant Products (Contd..7) ..................................................................................................... 304 

Pancreatic Cancer Therapeutics – Dormant Products (Contd..8) ..................................................................................................... 305 

Pancreatic Cancer Therapeutics – Dormant Products (Contd..9) ..................................................................................................... 306 

Pancreatic Cancer Therapeutics – Dormant Products (Contd..10) ................................................................................................... 307 

Pancreatic Cancer Therapeutics – Dormant Products (Contd..11) ................................................................................................... 308 

List of Figures

Number of Products under Development for Pancreatic Cancer, H1 2013 ........................................................................................ 16 

Products under Development for Pancreatic Cancer – Comparative Analysis, H1 2013 ................................................................... 17 

Products under Development by Companies, H1 2013 ...................................................................................................................... 18 

Products under Investigation by Universities/Institutes, H1 2013 ....................................................................................................... 32 

Late Stage Products, H1 2013 ............................................................................................................................................................. 35 

Mid Clinical Stage Products, H1 2013 ................................................................................................................................................. 36 

Early Clinical Stage Products, H1 2013 ............................................................................................................................................... 37 

Discovery and Pre-Clinical Stage Products, H1 2013 ......................................................................................................................... 38 

Assessment by Monotherapy Products, H1 2013 ............................................................................................................................. 216 

Assessment by Combination Products, H1 2013 .............................................................................................................................. 217 

Assessment by Route of Administration, H1 2013 ............................................................................................................................ 218 

Assessment by Stage and Route of Administration, H1 2013 .......................................................................................................... 219 

Assessment by Molecule Type, H1 2013 .......................................................................................................................................... 221 

Assessment by Stage and Molecule Type, H1 2013 ......................................................................................................................... 222 

SAMPLEPancreatic Cancer – Pipeline Review, H1 2013

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(14)

Introduction

Global Markets Direct Report Coverage

Global Markets Direct’s, Pancreatic Cancer – Pipeline Review, H1 2013, provides an overview into the pipeline. This report provides information on the current developmental pipeline, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews the key players and their products under development for Pancreatic Cancer.

It is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

SAMPLEPancreatic Cancer – Pipeline Review, H1 2013

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(15)

Pancreatic Cancer Overview

Pancreatic carcinoma is cancer of the pancreas. The pancreas is a large organ located behind the stomach. It makes and releases enzymes into the intestines that help the body absorb foods, especially fats. Hormones called insulin and glucagon, which help your body control blood sugar levels, are made in special cells in the pancreas called islet cells. Tumors can also occur in these cells, but they are called islet cell tumors.

SAMPLEPancreatic Cancer – Pipeline Review, H1 2013

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(16)

Therapeutics Development

An Overview of Pipeline Products for Pancreatic Cancer

Number of Products under Development for Pancreatic Cancer, H1 2013

Source: Global Markets Direct

Number of Products Under Development for Pancreatic Cancer, H1 2013

Stage of Development Number of Products Under Development

Pre-Registration

Filing rejected/Withdrawn

Phase III

Phase II

Phase II

Phase I

Phase I

IND/CTA Filed

Preclinical

Discovery

Status Unknown

Total

Source: Global Markets Direct

SAMPLEPancreatic Cancer – Pipeline Review, H1 2013

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(17)

Products under Development for Pancreatic Cancer – Comparative Analysis, H1 2013

Source: Global Markets Direct

Products under Development for Pancreatic Cancer – Comparative Analysis, H1 2013

Stage of Development Company Universities/Institutes

Pre-Registration

Filing rejected/Withdrawn

Phase III

Phase II

Phase II

Phase I

Phase I

IND/CTA Filed

Preclinical

Discovery

Status Unknown

Total

Source: Global Markets Direct

SAMPLEPancreatic Cancer – Pipeline Review, H1 2013

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(18)

Pancreatic Cancer Therapeutics under Development by Companies

Products under Development by Companies, H1 2013

Source: Global Markets Direct

SAMPLEPancreatic Cancer – Pipeline Review, H1 2013

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(19)

Number of Products under Development by Companies, H1 2013

Company Name Filed Phase III

Phase II

Phase I

Phase 0

IND Filed

Pre-Clinical

Discovery Status Unknown

Total

3-V Biosciences, Inc.

Ability Pharma, SL

Advaxis, Inc.

Alethia Biotherapeutics Inc.

Antisense Pharma GmbH

Antyra, Inc.

Apexigen, Inc.

APIM Therapeutics AS

Apogee Biotechnology Corporation

Arch Biopartners, Inc.

AREVA Med LLC

Ascenta Therapeutics, Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

Astrimmune

Source: Global Markets Direct

SAMPLEAppendix

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(318)

Appendix

Methodology

Global Markets Direct dedicated Research and Analysis Teams consists of experienced professionals with a pedigree in marketing, market research, consulting background in the pharmaceutical industry and advanced statistical expertise.

Global Markets Direct adheres to the Codes of Practice of the Market Research Society (www.mrs.org.uk) and the Strategic and Competitive Intelligence Professionals (www.scip.org).

All Global Markets Direct databases are continuously updated and revised. The following research methodology is followed for all databases and reports.

Coverage

The objective of updating Global Markets Direct coverage is to ensure that it represents the most up to date vision of the industry possible.

Changes the industry taxonomy are built on the basis of extensive research of company, association and competitor sources.Company coverage is based on three key factors: market capitalization, revenues and media attention/innovation/ market potential.An exhaustive search of 56 member exchanges is conducted and companies are prioritized on the basis of their market capitalization.The estimated revenues of all major companies, including private and governmental, are gathered and used to prioritize coverage.Companies which are making the news, or which are of particular interest due to their innovative approach are prioritized.Global Markets Direct aims to cover all major news events and deals in the pharmaceutical industry, updated on a daily basis.The coverage is further streamlined and strengthened with additional inputs from Global Markets Direct Expert Panel (see below).

Secondary Research

The research process begins with exhaustive secondary research on internal and external sources being carried out to source qualitative and quantitative information relating to each market.The secondary research sources that are typically referred to include, but are not limited to:Company websites, annual reports, financial reports, broker reports, investor presentations and SEC FilingsIndustry trade journals and other literatureInternal and external proprietary databasesNational government documents, statistical databases and market reportsNews articles, press releases and web-casts specific to the companies operating in the market

Primary Research

Global Markets Direct conducts hundreds of primary interviews a year with industry participants and commentators in order to validate its data and analysis. A typical research interview fulfills the following functions:It provides first-hand information on the market size, market trends, growth trends, competitive landscape, future outlook etcHelps in validating and strengthening the secondary research findingsFurther develops the Analyses Team’s expertise and market understandingPrimary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies.The participants who typically take part in such a process include, but are not limited to:Industry participants: CEOs, VPs, business development managers, market intelligence managers and national sales managersOutside experts: Investment Bankers, Valuation Experts, Research Analysts and key opinion leaders specializing in pharmaceutical industry

Expert Panel Validation

Global Markets Direct uses a panel of experts to cross verify research and forecast methodologies, and drive its analytical content.The Global Markets Direct expert panel comprises of marketing managers, product specialists, international sales managers from pharmaceutical companies; academics from research universities and consultants from professional services companies. Details of the make up of the expert panel can be viewed through website, and are available to clients on request.

SAMPLE

Appendix

Pancreatic Cancer – Pipeline Review, H1 2013 GMDHC3574IDB/ Pub May 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(319)

Disclaimer

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, Global Markets Direct.